New combo of radioactive drug and chemo tackles Hard-to-Treat breast cancer
NCT ID NCT06247995
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests a new approach for people with a specific type of advanced breast cancer (ER+/HER2-) that has stopped responding to hormone therapy. It combines a radioactive drug (lutetium NeoB) that targets cancer cells with a standard chemotherapy pill (capecitabine). The study has two parts: first, finding safe doses, and second, checking if the combination shrinks tumors. Only 20 participants are enrolled, so results are preliminary.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
lutetium NeoB (a radioactive drug) and capecitabine (chemotherapy)
What this could lead to
If it works, this could offer a new treatment option for people with advanced breast cancer that has stopped responding to hormone therapy.
What could go wrong
This is an early, small trial (20 people) focused on safety and dosing, so it may not lead to a proven treatment. The radioactive drug and chemo can cause side effects like fatigue, low blood counts, and organ damage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hoag Memorial Hospital Presbyterian
Newport Beach, California, 92663, United States
-
Mayo Clinic - Rochester
Rochester, Minnesota, 55905, United States
-
Novartis Investigative Site
Darlinghurst, New South Wales, 2010, Australia
-
Novartis Investigative Site
Malvern, Victoria, 3144, Australia
-
Novartis Investigative Site
Toronto, Ontario, M4N 3M5, Canada
-
Novartis Investigative Site
Montreal, Quebec, H3T 1E2, Canada
-
Novartis Investigative Site
Tianjin, 300300, China
-
Novartis Investigative Site
Grenoble, 38043, France
-
Novartis Investigative Site
Saint-Herblain, 44805, France
-
Novartis Investigative Site
Villejuif, 94800, France
-
Novartis Investigative Site
Erlangen, 91054, Germany
-
Novartis Investigative Site
Tübingen, 72076, Germany
-
Novartis Investigative Site
Delft, South Holland, 2625 AD, Netherlands
-
Novartis Investigative Site
Singapore, 168583, Singapore
-
Novartis Investigative Site
Seoul, 03080, South Korea
-
Novartis Investigative Site
Seoul, 05505, South Korea
-
Novartis Investigative Site
L'Hospitalet de Llobregat, Barcelona, 08907, Spain
-
Novartis Investigative Site
Barcelona, 08036, Spain
-
Novartis Investigative Site
Madrid, 28041, Spain
-
UCLA Medical Center
Los Angeles, California, 90095, United States
-
Uni Of TX MD Anderson Cancer Cntr
Houston, Texas, 77030, United States
-
University Of Wisconsin
Madison, Wisconsin, 53792, United States